QuidelOrtho (QDEL) Competitors $38.05 -0.94 (-2.41%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends QDEL vs. MYGN, CLDX, VIVO, NTLA, HSKA, MMSI, XRAY, ICUI, HAE, and NEOGShould you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Heska (HSKA), Merit Medical Systems (MMSI), DENTSPLY SIRONA (XRAY), ICU Medical (ICUI), Haemonetics (HAE), and Neogen (NEOG). These companies are all part of the "medical" sector. QuidelOrtho vs. Myriad Genetics Celldex Therapeutics Meridian Bioscience Intellia Therapeutics Heska Merit Medical Systems DENTSPLY SIRONA ICU Medical Haemonetics Neogen QuidelOrtho (NASDAQ:QDEL) and Myriad Genetics (NASDAQ:MYGN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment. Does the MarketBeat Community believe in QDEL or MYGN? Myriad Genetics received 25 more outperform votes than QuidelOrtho when rated by MarketBeat users. However, 67.33% of users gave QuidelOrtho an outperform vote while only 53.36% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformQuidelOrthoOutperform Votes44367.33% Underperform Votes21532.67% Myriad GeneticsOutperform Votes46853.36% Underperform Votes40946.64% Which has more volatility and risk, QDEL or MYGN? QuidelOrtho has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Does the media prefer QDEL or MYGN? In the previous week, QuidelOrtho and QuidelOrtho both had 4 articles in the media. QuidelOrtho's average media sentiment score of 1.24 beat Myriad Genetics' score of 1.18 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate QDEL or MYGN? QuidelOrtho presently has a consensus price target of $58.83, indicating a potential upside of 52.14%. Myriad Genetics has a consensus price target of $28.91, indicating a potential upside of 29.99%. Given QuidelOrtho's higher probable upside, equities research analysts plainly believe QuidelOrtho is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29Myriad Genetics 2 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.42 Which has preferable earnings and valuation, QDEL or MYGN? QuidelOrtho has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuidelOrtho$3.00B0.86-$10.10M-$27.79-1.39Myriad Genetics$753.20M2.68-$263.30M-$1.81-12.30 Do institutionals and insiders believe in QDEL or MYGN? 99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 1.0% of QuidelOrtho shares are held by company insiders. Comparatively, 2.1% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is QDEL or MYGN more profitable? Myriad Genetics has a net margin of -19.35% compared to QuidelOrtho's net margin of -65.60%. QuidelOrtho's return on equity of 3.87% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets QuidelOrtho-65.60% 3.87% 2.09% Myriad Genetics -19.35%-5.64%-3.73% SummaryMyriad Genetics beats QuidelOrtho on 9 of the 17 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get QuidelOrtho News Delivered to You Automatically Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QDEL vs. The Competition Export to ExcelMetricQuidelOrthoDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$2.63B$5.37B$8.41BDividend YieldN/A0.69%5.21%4.20%P/E Ratio-1.396.35140.7917.72Price / Sales0.8630.641,454.6778.04Price / Cash3.5216.4938.9433.56Price / Book0.513.154.744.59Net Income-$10.10M$29.98M$115.38M$225.45M7 Day Performance-0.75%-2.51%-0.54%-0.23%1 Month Performance-15.57%1.66%3.93%1.90%1 Year Performance-36.97%0.72%39.33%33.46% QuidelOrtho Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QDELQuidelOrtho4.3904 of 5 stars$38.05-2.4%$58.83+54.6%-35.2%$2.56B$2.83B-1.377,100Upcoming EarningsNews CoverageMYGNMyriad Genetics4.4915 of 5 stars$22.26-2.2%$28.91+29.9%+57.3%$2.02B$753.20M-12.302,700Upcoming EarningsPositive NewsCLDXCelldex Therapeutics2.0237 of 5 stars$25.82-1.9%$62.25+141.1%+16.0%$1.71B$8.30M-9.42160Upcoming EarningsAnalyst ForecastVIVOMeridian Bioscience1.0451 of 5 stars$33.97flatN/AN/A$1.50B$333.02M35.02702NTLAIntellia Therapeutics4.102 of 5 stars$14.37+0.3%$59.13+311.5%-39.9%$1.46B$36.28M-2.62600HSKAHeskaN/A$119.99flatN/AN/A$1.31B$257.31M-62.17808MMSIMerit Medical Systems4.5638 of 5 stars$99.12+4.4%$103.00+3.9%+42.8%$5.76B$1.30B49.566,950Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsXRAYDENTSPLY SIRONA4.7434 of 5 stars$23.34-0.3%$32.67+40.0%-21.9%$4.73B$3.97B-27.1415,000Upcoming EarningsAnalyst UpgradeShort Interest ↓ICUIICU Medical4.0565 of 5 stars$171.75-2.1%$170.25-0.9%+78.2%$4.18B$2.30B-58.8214,000HAEHaemonetics4.8456 of 5 stars$71.50-0.7%$106.14+48.5%-15.2%$3.64B$1.33B32.063,657Upcoming EarningsNEOGNeogen2.5572 of 5 stars$14.45-0.8%$17.50+21.1%-3.3%$3.13B$912.20M-131.362,640Positive News Related Companies and Tools Related Companies Myriad Genetics Alternatives Celldex Therapeutics Alternatives Meridian Bioscience Alternatives Intellia Therapeutics Alternatives Heska Alternatives Merit Medical Systems Alternatives DENTSPLY SIRONA Alternatives ICU Medical Alternatives Haemonetics Alternatives Neogen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QDEL) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
